What is it used for?
ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test , with disease progression following at least one line of endocrine therapy.ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test , with disease progression following at least one line of endocrine therapy.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- elacestrantelacestrant
- Form and strength
- TABLET, FILM COATED · 86 mg; TABLET, FILM COATED · 345 mgTABLET, FILM COATED · 86 mg; TABLET, FILM COATED · 345 mg
- Manufacturer / applicant
- STEMLINE THERAPEUTICS, INC.STEMLINE THERAPEUTICS, INC.
Tablets: Elacestrant 345 mg (equivalent to 400 mg elacestrant hydrochloride) and 86 mg (equivalent to 100 mg elacestrant hydrochloride): 345 mg: light blue, unscored, oval film-coated biconvex tablet, imprinted with “MH” on one side and plain on the …Tablets: Elacestrant 345 mg (equivalent to 400 mg elacestrant hydrochloride) and 86 mg (equivalent to 100 mg elacestrant hydrochloride): 345 mg: light blue, unscored, oval film-coated biconvex tablet, imprinted with “MH” on one side and plain on the …
Safety and clinical review
- DyslipidemiaDyslipidemia
- Embryo-Fetal ToxicityEmbryo-Fetal Toxicity
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is ORSERDU used for?
ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test , with disease progression following at least one line of endocrine therapy.ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test , with disease progression following at least one line of endocrine therapy.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of ORSERDU should I ask about?
TABLET, FILM COATED · 86 mg; TABLET, FILM COATED · 345 mgTABLET, FILM COATED · 86 mg; TABLET, FILM COATED · 345 mg
Read the primary sourceWhat determines the price of ORSERDU?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using ORSERDU?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.